Komodo Health names Miles Ennis President in Executive leadership shift. June 16, 2026 Miles Ennis Komodo Health has named Miles Ennis President and elevated co-founder Web Sun to co-Chief Executive Officer, updating its leadership structure as the healthcare intelligence company looks to scale adoption of its AI platform across healthcare and life sciences organizations. Sun will serve as co-CEO alongside co-founder and CEO Arif Nathoo, M.D., while Ennis will take on expanded responsibility for commercial execution, operations, product strategy alignment and marketing. The company said the changes are intended to support its next phase of growth as customers move from artificial intelligence pilots toward broader enterprise deployment. Komodo's platform strategy centers on Marmot, its healthcare-native AI analytics platform, which is designed to help organizations generate verifiable and reproducible evidence from healthcare data. The company positions Marmot as an enterprise intelligence layer for life sciences and healthcare teams seeking faster answers to complex questions across clinical development, market access, commercialization and real-world evidence. "The next era of healthcare AI will be defined by vertical AI platforms that combine deep domain expertise, trusted data foundations, and purpose-built intelligence, and we believe Komodo is positioned to lead that category," Nathoo said. "We have tremendous confidence in the opportunity ahead and are committed to continuing to invest in our platform, our people, and our partners to meet the growing demand for healthcare-native AI." Ennis joined Komodo as Chief Revenue Officer in July 2024 and was named Chief Operating Officer in September 2025. Since joining the company, he has helped drive commercialization of Marmot and expand strategic relationships across Komodo's partner ecosystem. As President, Ennis will focus on scaling the company's go-to-market organization and strengthening operational execution as demand grows for AI tools built specifically for healthcare and life sciences workflows. His responsibilities will include aligning product innovation with customer needs and helping ensure the platform delivers measurable value across enterprise deployments. "Healthcare and Life Sciences organizations are moving beyond AI pilots and looking for solutions that work at enterprise scale, built on data they can trust and a platform designed for the complexity of healthcare," Ennis said. "That is exactly what Komodo delivers, and as President, my focus will be to ensure our platform delivers measurable value and impact for the organizations we serve." The leadership shift comes as healthcare companies, pharmaceutical manufacturers and life sciences organizations increasingly seek AI systems that can operate within highly regulated, data-intensive environments. For those customers, the ability to produce transparent, auditable and reproducible outputs is becoming central to enterprise adoption. Komodo's Healthcare Map includes more than 330 million de-identified patient journeys, providing the data foundation for its analytics and AI tools. The company said Marmot is designed to help teams move from business or clinical questions to decisions more quickly while maintaining transparency and auditability. Sun said the updated leadership model reflects both the scale of the company's opportunity and the complexity of its next growth phase. "This evolved leadership structure reflects the scale of the opportunity ahead and the operating complexity of this next phase of growth," Sun said. "Miles has consistently demonstrated the ability to connect strategy, product innovation, customer needs, and execution, a capability that becomes even more important as AI reshapes what is possible in healthcare and Life Sciences." Komodo Health provides AI-powered healthcare intelligence for organizations working across clinical development, market access, commercialization and real-world evidence. Through its Healthcare Map and Marmot platform, the company aims to support faster, more reliable decision-making in healthcare and life sciences markets where data quality, workflow integration and evidence generation are critical to scaling AI use.

Komodo Health appoints Paul Thomas as Chief Financial Officer. Finance veteran to oversee financial strategy as demand for company's AI platform accelerates. NEW YORK & SAN FRANCISCO - April 30, 2026 - Komodo Health, the leader in AI-powered healthcare intelligence, today announced the promotion of Paul Thomas to Chief Financial Officer (CFO). In this role, Thomas, who has served as Senior Vice President of Finance and Acting CFO since April 2025, will oversee Komodo's finance organization and enterprise financial strategy. The appointment comes as the industry reaches an inflection point, with organizations moving beyond using AI as a productivity layer to building and operationalizing it as a core enterprise capability. Komodo is leading this shift with Marmot(TM), its AI analytics platform built on the Healthcare Map(R), the industry's most comprehensive view of 330+ million patient journeys. Marmot enables organizations to move from static reporting and delayed insights to real-time, trusted intelligence and accelerate critical decision-making across the product life cycle, from trial design to launch strategy to post-market evidence generation. As adoption of Marmot increases across healthcare and Life Sciences organizations, the ability to align capital allocation, investment strategy, and long-term platform development is essential to sustaining growth. "Paul's expertise has been instrumental in advancing Komodo's strong financial foundation and positioning us for our next phase of AI-led growth," said Web Sun, President and Co-Founder, Komodo Health. "As our customers move from treating AI as a productivity tool to embedding it as a core part of how they operate, the discipline and strategic alignment he brings will be essential as we continue to scale." Since joining Komodo Health, Thomas has played a central role in strengthening the company's financial strategy, improving operational rigor and enabling disciplined investment across product innovation and go-to-market expansion. His leadership has helped ensure that Komodo can scale aggressively while continuing to invest in the infrastructure required to support enterprise-grade AI development and deployment. "Komodo is building the AI-powered intelligence that is fundamentally changing how organizations make decisions," said Thomas. "My focus is on ensuring we have the financial strategy, systems, and discipline to support that growth while continuing to invest in the platform and capabilities that drive impact for our customers." Thomas brings more than 20 years of experience in private and public company finance, strategic planning, and investment research. Prior to Komodo Health, he led Strategic Finance and Investor Relations at Talkdesk and played a key role in taking Sumo Logic public in 2020. He began his career as a semiconductor engineer at Intel Corporation before moving into finance roles at Merrill Lynch, Bank of America, and Goldman Sachs. About Komodo Health Komodo Health is on a mission to reduce the global burden of disease by building foundational AI for how Life Sciences and healthcare organizations discover, develop, and deliver life-saving therapies. The company's healthcare-native AI platform Marmot, powered by its Healthcare Map, eliminates slow, fragmented analyses to accelerate critical healthcare decisions across the product life cycle - from trial design to launch strategy to post-market evidence generation. For more information, visit www.komodohealth.com.

Real-World Kidney Cancer Insights from 10 Key cities. Apr. 08. 2026 Kidney Cancer Association This is an excerpt from the blog "Uneven Terrain: How Local Real-World Insights Can Improve Kidney Cancer Outcomes" by Komodo Health. The Kidney Cancer Association partners with Komodo Health, an AI-powered life sciences company uncovering the complex factors that contribute to the patient journey. Read the detailed report: "Uneven Terrain: Using Real-World Evidence to Understand Regional Differences in Kidney Cancer". Nearly 81,000 Americans will be newly diagnosed with kidney cancer this year, and incidence has continued to rise over the past two decades. But national statistics only tell part of the story. A patient's experience with kidney cancer - when it's diagnosed, how advanced it is, and how many providers are able to diagnose and treat it - can look very different depending on where they live. Understanding these local differences is essential for improving patient outcomes. Strategies that work well in one region may fall short in another if they don't account for variations in disease burden, patient demographics, or healthcare capacity. To better understand these dynamics, Komodo Health has partnered with the Kidney Cancer Association (KCA) during National Kidney Awareness Month to examine kidney cancer across 10 major U.S. metropolitan areas (Atlanta, GA; Bay Area, CA; Chicago, IL; Dallas/Fort Worth, TX; Durham-Chapel Hill, NC; Houston, TX; New York City, NY; Philadelphia, PA; Phoenix, AZ; Seattle, WA). This analysis used Komodo's healthcare-native AI analytics platform, Marmot(TM). Where disease burden and system capacity diverge. The analysis revealed meaningful differences across metropolitan areas in both disease burden and healthcare capacity. Rates of kidney cancer in these areas varied widely, ranging from approximately 123 cases per 100,000 people in Seattle to nearly 202 per 100,000 in Phoenix. Several West Coast metro areas, including the Bay Area and Seattle, exhibited a disproportionately high share of metastatic disease within their kidney cancer population. In these regions, more than 22% of patients were diagnosed with metastatic kidney cancer, compared with the national rate of 18.4%, with increases across age groups. Patient age distributions also differed by region. In Atlanta, pediatric patients accounted for up to 1.8% of cases, higher than the metro average of 1.2%. In cities such as Chicago, Phoenix, and Durham-Chapel Hill, patients age 65 and older made up more than two-thirds of all cases. In parallel, diagnostic capacity did not always track with disease burden. Some large metros combined lower metastatic shares with higher patient-to-provider ratios. For example, New York City had an average of 1.4 kidney cancer patients per diagnosing provider versus 1.1 across large metros, suggesting differences in diagnostic capacity and care pathways. From the report: Key Findings * Kidney cancer prevalence ranged widely across U.S. metropolitan areas, from ~123 per 100K in Seattle to ~202 per 100K in Philadelphia. * West Coast metros, particularly the Bay Area and Seattle, showed metastatic rates well above the national average. * New York City had the highest patient-to-provider ratio among metros (1.4 vs. 1.1). * Higher shares of pediatric kidney cancer patients were seen in Atlanta and Seattle, and higher shares of young adult patients (ages 25-44) in Dallas/Fort Worth, Houston, and Seattle. Executive Summary Nearly 81,000 Americans will be newly diagnosed with kidney cancer this year, and incidence has continued to rise over the past two decades. Rates vary considerably across the U.S., shaped by population characteristics, environmental and lifestyle factors, and access to timely care. National rates often obscure the realities patients face locally. Real-world evidence (RWE) makes these differences visible - revealing where disease burden is highest, where advanced disease is more common, and where diagnostic capacity may be under strain. This level of geographic specificity is foundational for shaping effective advocacy, outreach, and institutional partnerships. The findings reveal distinct regional profiles of kidney cancer burden, metastatic disease, and provider patient-to-provider ratio, highlighting areas where targeted advocacy, education, and system-level interventions may yield the greatest benefit. Read the full blog and the detailed report. Your email address will not be published. Required fields are marked *